Abstract
The reasons why treatment of Parkinson's disease with the combination L Dopa+decarboxylase inhibitor ('Benserazide') is better than with L Dopa alone are presented. Experimental and clinical results obtained by other authors with this combination drug are extensively reported. Observations on the treatment of 45 Parkinsonian patients with 'Madopar' (L Dopat 'Benserazide') for a period up to 3 yr are reported. Thirty seven patients had a moderate to good improvement in their symptomatology, 8 other patients showed a slight response to the treatment. An appreciable improvement was shown in tremor, which was scarcely influenced by L Dopa alone. A satisfactory stability of the therapeutic effectiveness was observed during 3 yr. 'Peripheral' side effects were minimized by the combination drug, 'central' side effects were only slightly less frequent in comparison with those reported with L Dopa alone.
| Original language | Italian |
|---|---|
| Pages (from-to) | 303-330 |
| Number of pages | 28 |
| Journal | Rivista di Neurologia |
| Volume | 44 |
| Issue number | 5 |
| Publication status | Published - 1974 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
RISULTATI DEL TRATTAMENTO PROLUNGATO DEL MORBO DI PARKINSON CON L'ASSOCIAZIONE L DOPA + BENSERAZIDE. / Casacchia, M.; Barba, C.; Ruggieri, S.; Zamponi, A.; Agnoli, A.
In: Rivista di Neurologia, Vol. 44, No. 5, 1974, p. 303-330.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - RISULTATI DEL TRATTAMENTO PROLUNGATO DEL MORBO DI PARKINSON CON L'ASSOCIAZIONE L DOPA + BENSERAZIDE
AU - Casacchia, M.
AU - Barba, C.
AU - Ruggieri, S.
AU - Zamponi, A.
AU - Agnoli, A.
PY - 1974
Y1 - 1974
N2 - The reasons why treatment of Parkinson's disease with the combination L Dopa+decarboxylase inhibitor ('Benserazide') is better than with L Dopa alone are presented. Experimental and clinical results obtained by other authors with this combination drug are extensively reported. Observations on the treatment of 45 Parkinsonian patients with 'Madopar' (L Dopat 'Benserazide') for a period up to 3 yr are reported. Thirty seven patients had a moderate to good improvement in their symptomatology, 8 other patients showed a slight response to the treatment. An appreciable improvement was shown in tremor, which was scarcely influenced by L Dopa alone. A satisfactory stability of the therapeutic effectiveness was observed during 3 yr. 'Peripheral' side effects were minimized by the combination drug, 'central' side effects were only slightly less frequent in comparison with those reported with L Dopa alone.
AB - The reasons why treatment of Parkinson's disease with the combination L Dopa+decarboxylase inhibitor ('Benserazide') is better than with L Dopa alone are presented. Experimental and clinical results obtained by other authors with this combination drug are extensively reported. Observations on the treatment of 45 Parkinsonian patients with 'Madopar' (L Dopat 'Benserazide') for a period up to 3 yr are reported. Thirty seven patients had a moderate to good improvement in their symptomatology, 8 other patients showed a slight response to the treatment. An appreciable improvement was shown in tremor, which was scarcely influenced by L Dopa alone. A satisfactory stability of the therapeutic effectiveness was observed during 3 yr. 'Peripheral' side effects were minimized by the combination drug, 'central' side effects were only slightly less frequent in comparison with those reported with L Dopa alone.
UR - http://www.scopus.com/inward/record.url?scp=0016150258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016150258&partnerID=8YFLogxK
M3 - Articolo
C2 - 4217465
AN - SCOPUS:0016150258
VL - 44
SP - 303
EP - 330
JO - Rivista di Neurologia
JF - Rivista di Neurologia
SN - 0035-6344
IS - 5
ER -